These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8453691)

  • 61. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
    Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
    J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
    van Warmerdam LJ; Verweij J; Schellens JH; Rosing H; Davies BE; de Boer-Dennert M; Maes RA; Beijnen JH
    Cancer Chemother Pharmacol; 1995; 35(3):237-45. PubMed ID: 7805183
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
    Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
    Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 68. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL; Malmström H; Peterson C
    Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent.
    Stein CA; Khan TM; Khaled Z; Tonkinson JL
    Clin Cancer Res; 1995 May; 1(5):509-17. PubMed ID: 9816010
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
    Britten CD; Rowinsky EK; Baker SD; Weiss GR; Smith L; Stephenson J; Rothenberg M; Smetzer L; Cramer J; Collins W; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2000 Jan; 6(1):42-9. PubMed ID: 10656430
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
    Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
    Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs.
    Kurata N; Imabeppu S; Nitoh M; Kobayashi H; Kuwabara T; Kobayashi S
    J Pharm Pharmacol; 2000 Nov; 52(11):1327-35. PubMed ID: 11186240
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
    Curtis KK; Hartney JT; Jewell RC; Park JW; Lebowitz PF; Griffin PP; Borad MJ; Fitch TR; Northfelt DW
    J Clin Pharmacol; 2010 Mar; 50(3):268-75. PubMed ID: 19808951
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
    Perez-Ruixo JJ; Piotrovskij V; Zhang S; Hayes S; De Porre P; Zannikos P
    Br J Clin Pharmacol; 2006 Jul; 62(1):81-96. PubMed ID: 16842381
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells.
    Baghdiguian S; Boudier JA; Boudier JL; Fantini J
    Cancer Lett; 1996 Mar; 101(2):179-84. PubMed ID: 8620467
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.
    Olver IN; Webster LK; Bishop JF; Stokes KH
    Cancer Chemother Pharmacol; 1992; 29(5):354-60. PubMed ID: 1551173
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
    J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.